Veru (VERU) Research & Development (2016 - 2026)
Veru's Research & Development came in at $4.35 million for fiscal Q3 2026 (quarter ended Jun 30, 2026), up 44.1% from $3.02 million a year earlier and up 38.4% from the prior quarter.
Powered by 
Analysis
Veru (VERU) Research & Development (2016 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Veru reported Research & Development of $11.86 million, down 25.8% year-over-year; for FY2024 (ended Sep 30, 2024), it came in at $12.81 million, down 75.0% from FY2023.
- Research & Development carries a five-year compound annual growth rate of -1.4% (FY2019 to FY2024).
- Going back by fiscal year, Research & Development was $51.2 million in FY2023 (-27.8%), $70.91 million in FY2022 (+116.9%), $32.69 million in FY2021 (+93.1%) and $16.94 million in FY2020 (+23.2%).
- The fiscal Q3 2026 figure represents the highest quarterly Research & Development since fiscal Q1 2025.
- Year-over-year, Research & Development increased in three of the last seven quarters, with growth averaging 24.4%.
- The fastest year-over-year change in Research & Development over five years came in fiscal Q1 2025 (growth of 244.7%), and the weakest in fiscal Q1 2024 (a decline of 92.0%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Veru | 58.32 Mn | -51.96 Mn | - | 4.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.35 Mn |
| Mar 31, 2026 | 3.15 Mn |
| Dec 31, 2025 | 1.34 Mn |
| Jun 30, 2025 | 3.02 Mn |
| Mar 31, 2025 | 3.93 Mn |
| Dec 31, 2024 | 5.72 Mn |
| Sep 30, 2024 | 3.32 Mn |
| Jun 30, 2024 | 4.85 Mn |
| Mar 31, 2024 | 2.99 Mn |
| Dec 31, 2023 | 1.66 Mn |
| Sep 30, 2023 | 3.94 Mn |
| Jun 30, 2023 | 8.79 Mn |
| Mar 31, 2023 | 17.86 Mn |
| Dec 31, 2022 | 20.61 Mn |
| Sep 30, 2022 | 27.16 Mn |
| Jun 30, 2022 | 18.13 Mn |
| Mar 31, 2022 | 15.54 Mn |
| Dec 31, 2021 | 10.08 Mn |
| Sep 30, 2021 | 8.26 Mn |
| Jun 30, 2021 | 11.19 Mn |
API Access
Veru Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=VERU&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "VERU", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=VERU&period=max&api_key=YOUR_API_KEY");
const data = await res.json();